NovaBridge Biosciences (NBP)Healthcare | Biotechnology | Rockville, United States | NasdaqGM
2.70 USD
+0.03
(1.124%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.70 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:36 p.m. EDT
NovaBridge Biosciences (NBP) is currently trading near its 52-week low, with a negative forward PE and trailing EPS, indicating weak earnings performance. The recent price history shows volatility, with a recent dip below the 50-day average, suggesting short-term weakness. The lack of dividend history and the high short ratio indicate potential short-term volatility and uncertainty. While insider buying and positive analyst recommendations suggest some confidence in the stock, the overall fundamental and technical indicators point to a cautious approach. Investors should consider the high volatility and lack of dividend yield before making any decisions. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.292361 |
| AutoARIMA | 0.296897 |
| AutoTheta | 0.316245 |
| MSTL | 0.321755 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 8.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.154 |
| Excess Kurtosis | -1.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.328 |
| Market Cap | 312,250,976 |
| Forward P/E | -2.55 |
| Beta | 1.74 |
| Website | https://www.novabridge.com |
As of April 11, 2026, 1:36 p.m. EDT: The options data suggests a mixed sentiment. For calls, there is a notable amount of open interest (OI) and volume on out-of-the-money (OTM) strikes, particularly for the 2026-04-17 and 2026-07-17 expirations, indicating potential bullish speculation on higher price movements. However, the put options show significant OI on OTM strikes, suggesting some bearish sentiment. The IV (implied volatility) for calls is higher on certain expirations, indicating increased uncertainty or speculation about future price movements. Overall, the options activity shows a balance between bullish and bearish bets, with no clear consensus on the direction.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.1578948 |
| Address1 | 2,440 Research Boulevard |
| Address2 | Suite 400 |
| All Time High | 85.4 |
| All Time Low | 0.595 |
| Ask | 2.73 |
| Ask Size | 10 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 859,880 |
| Average Daily Volume3 Month | 786,454 |
| Average Volume | 786,454 |
| Average Volume10Days | 859,880 |
| Beta | 1.743 |
| Bid | 2.66 |
| Bid Size | 10 |
| Book Value | 2.002 |
| City | Rockville |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.7 |
| Current Ratio | 8.088 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.77 |
| Day Low | 2.645 |
| Debt To Equity | 1.328 |
| Earnings Timestamp | 1,775,592,000 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -94,201,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.418 |
| Enterprise Value | 510,402,208 |
| Eps Current Year | -0.94 |
| Eps Forward | -1.06 |
| Eps Trailing Twelve Months | -0.48 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9437 |
| Fifty Day Average Change | -0.24370003 |
| Fifty Day Average Change Percent | -0.08278698 |
| Fifty Two Week Change Percent | 215.78949 |
| Fifty Two Week High | 6.79 |
| Fifty Two Week High Change | -4.09 |
| Fifty Two Week High Change Percent | -0.60235643 |
| Fifty Two Week Low | 0.801 |
| Fifty Two Week Low Change | 1.899 |
| Fifty Two Week Low Change Percent | 2.3707867 |
| Fifty Two Week Range | 0.801 - 6.79 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,579,271,400,000 |
| Float Shares | 148,734,501 |
| Forward Eps | -1.06 |
| Forward P E | -2.54717 |
| Free Cashflow | -37,113,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 30 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21327 |
| Held Percent Institutions | 0.42360002 |
| Implied Shares Outstanding | 115,648,505 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland. |
| Long Name | NovaBridge Biosciences |
| Market | us_market |
| Market Cap | 312,250,976 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_642067965 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -88,340,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 312,250,962 |
| Number Of Analyst Opinions | 4 |
| Open | 2.68 |
| Operating Cashflow | -20,597,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 240 745 6330 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.7 |
| Post Market Time | 1,776,458,402 |
| Previous Close | 2.67 |
| Price Eps Current Year | -2.8723404 |
| Price Hint | 4 |
| Price To Book | 1.3486513 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.906 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.03 |
| Regular Market Change Percent | 1.12359 |
| Regular Market Day High | 2.77 |
| Regular Market Day Low | 2.645 |
| Regular Market Day Range | 2.645 - 2.77 |
| Regular Market Open | 2.68 |
| Regular Market Previous Close | 2.67 |
| Regular Market Price | 2.7 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,096,653 |
| Return On Assets | -0.24902001 |
| Return On Equity | -0.40889 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 115,648,505 |
| Shares Percent Shares Out | 0.044 |
| Shares Short | 5,089,001 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,546,038 |
| Short Name | NovaBridge Biosciences |
| Short Percent Of Float | 0.0979 |
| Short Ratio | 5.32 |
| Source Interval | 15 |
| State | MD |
| Symbol | NBP |
| Target High Price | 9.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 8.25 |
| Target Median Price | 8.5 |
| Total Cash | 210,842,000 |
| Total Cash Per Share | 0.793 |
| Total Debt | 3,067,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.48 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.661075 |
| Two Hundred Day Average Change | -0.96107507 |
| Two Hundred Day Average Change Percent | -0.2625117 |
| Type Disp | Equity |
| Volume | 1,096,653 |
| Website | https://www.novabridge.com |
| Zip | 20,850 |